Bimagrumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | ACVR2B |
| Clinical data | |
| Other names | BYM338 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6306H9732N1684O1990S46 |
| Molar mass | 142451.78 g·mol−1 |
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B.
Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half life and is administered once a month.